PT - JOURNAL ARTICLE AU - Bal, Antonin AU - Brengel-Pesce, Karen AU - Gaymard, Alexandre AU - Quéromès, Grégory AU - Guibert, Nicolas AU - Frobert, Emile AU - Bouscambert, Maude AU - Trabaud, Mary-Anne AU - Allantaz-Frager, Florence AU - Oriol, Guy AU - Cheynet, Valérie AU - d’Aubarede, Constance AU - Massardier-Pilonchery, Amélie AU - Buisson, Marlyse AU - Lupo, Julien AU - Pozzetto, Bruno AU - Poignard, Pascal AU - Lina, Bruno AU - Fassier, Jean-Baptiste AU - Morfin-Sherpa, Florence AU - Trouillet-Assant, Sophie AU - , TI - Clinical and microbiological assessments of COVID-19 in healthcare workers: a prospective longitudinal study AID - 10.1101/2020.11.04.20225862 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.04.20225862 4099 - http://medrxiv.org/content/early/2020/11/06/2020.11.04.20225862.short 4100 - http://medrxiv.org/content/early/2020/11/06/2020.11.04.20225862.full AB - Background A comprehensive assessment of COVID-19 in healthcare workers (HCWs) including the investigation of viral shedding duration is critical.Methods A longitudinal study including 319 HCWs was conducted. After SARS-CoV-2 screening with RT-PCR assay, other respiratory pathogens were tested with a multiplex molecular panel. For SARS-CoV-2 positive HCWs, the normalized viral load was determined weekly; viral culture and virus neutralization assays were also performed. For 190 HCWs tested negative, SARS-CoV-2 serological testing was performed one month after the inclusion.Findings Of the 319 HCWs included, 67 (21.0%) were tested positive for SARS-CoV-2; two of them developed severe COVID-19. The proportion of smell and taste dysfunction was significantly higher in SARS-CoV-2 positive HCWs than in negative ones (38.8% vs 9.5% and 37.3% vs 10.7%, respectively, p<0.001). Of the 67 positive patients, 9.1% were tested positive for at least another respiratory pathogen (vs 19.5%, p=0.07). The proportion of HCWs with a viral load > 5.0 log10 cp/ml (Ct value <25) was less than 15% at 8 days after symptom onset; 12% of them were still positive after 40 days (Ct >37). More than 90% of culturable virus had a viral load > 4.5 log10 cp/ml (Ct < 26) and were collected within 10 days after symptom onset. From HCWs tested negative, 6/190 (3.2%) exhibited seroconversion for IgG antibodies.Interpretation Our data suggest that the determination of normalized viral load (or its estimation through Ct values) can be useful for discontinuing isolation of HCWs and facilitating their safe return to work. HCWs presenting mild COVID-19 are unlikely infectious 10 days after symptom onset.Funding Fondation des Hospices Civils de Lyon. bioMérieux provided diagnostic kits.Competing Interest StatementSeveral authors (KBP, FAF, GO, VC) are bioMerieux employees. AB has received a grant from bioMerieux and has served as consultant for bioMerieux. KBP, FAF, GO VC and AB were involved in data analysis, interpretation and wrote the article.Clinical TrialNCT04341142Funding StatementThis research is being supported by Hospices Civils de Lyon and by Fondation des Hospices Civils de Lyon. The bioMerieux employees were involved in data analysis, interpretation and wrote the article. bioMerieux provided qRT-PCr Argene kits and BIOFIRE Respiratory 2.1 plus Panel (RP2.1plus) kits for the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from all participants and approval was obtained from the national review board for biomedical research in April 2020 (Comite de Protection des Personnes Sud Mediterranee I, Marseille, France; ID RCB 2020-A00932-37).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript